Celularity (CELU) Net Equity Issued and Repurchased (2025)
Celularity (CELU) posted quarterly Net Equity Issued and Repurchased of -$1.4 million for Q3 2025, down 157.93% quarter-over-quarter from $2.5 million in Q1 2025.
Celularity (CELU) Net Equity Issued and Repurchased (2025) Analysis & Trends
Celularity (CELU) has reported Net Equity Issued and Repurchased for 1 consecutive years, with -$1.4 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$1.4 million; the TTM figure through Dec 2025 stood at $1.0 million (changed N/A YoY), while the FY2025 annual figure was $1.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased retreated to -$1.4 million in Q3 2025 per CELU's latest filing, from $2.5 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $2.5 million in Q1 2025 and bottomed at -$1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | 2.46 Mn |
| Mar 31, 2025 | 2.46 Mn |